Top

Published in:

01-09-2013 | Original Research Article

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

Authors: Barbara J. Brennan, Sebastian A. Moreira, Peter N. Morcos, Mercidita T. Navarro, Jiney Asthappan, Petra Goelzer, Paul Weigl, Patrick F. Smith

Published in: Clinical Pharmacokinetics | Issue 9/2013

Abstract

Background

Danoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease, which is currently in development in combination with low-dose ritonavir for the treatment of chronic hepatitis C infection. Danoprevir is a substrate of cytochrome P450 3A4, and the organic anion transporting polypeptides (OATP) 1B1 and 1B3.

Objective

The objective of this study was to evaluate the effect of a potent OATP inhibitor, ciclosporin, on danoprevir pharmacokinetics, when administered as danoprevir/ritonavir. The effect of danoprevir/ritonavir on ciclosporin pharmacokinetics was also investigated.

Methods

This was a single-dose, randomized, open-label, two-sequence, three-period, crossover study in healthy volunteers. In the first period, subjects were randomized to receive either a single oral dose of danoprevir 100 mg in combination with ritonavir 100 mg or a single oral dose of ciclosporin 100 mg. After a 14-day washout, patients were crossed over to receive the opposite treatment. In period 3, all subjects received the combination of danoprevir/ritonavir and ciclosporin following a 14-day washout from period 2. Blood samples were collected serially with each dose for pharmacokinetic assessment. Pharmacokinetic parameters were estimated using non-compartmental analysis. Geometric mean ratios (GMRs) and 90 % confidence intervals (CIs) were used to compare pharmacokinetic parameters [maximum concentration (C _max), area under the concentration–time curve from time zero to infinity (AUC_∞), and concentration 12 h post-dose (C _12h)] of danoprevir/ritonavir and ciclosporin when administered alone or in combination. Measures of safety and tolerability were also evaluated.

Results

A total of 18 subjects were enrolled, and 17 completed the study. The C _max, AUC_∞, and C _12h GMRs (90 % CI) when danoprevir/ritonavir and ciclosporin were co-administered versus danoprevir/ritonavir or ciclosporin alone were 7.22 (5.42–9.62), 13.6 (11.2–16.6), and 22.5 (17.4–29.3), respectively, for danoprevir, 1.97 (1.72–2.27), 2.23 (2.07–2.42), and 2.50 (2.22–2.81), respectively, for ritonavir, and 1.42 (1.29–1.57), 3.65 (3.27–4.08), and 6.15 (5.32–7.11), respectively, for ciclosporin. All treatments were well tolerated, with no laboratory abnormalities, and no clinically significant changes in vital signs, electrocardiograms, or physical examinations observed.

Conclusions

A significant drug–drug interaction was observed between ciclosporin and danoprevir/ritonavir, leading to substantial increases in exposure to danoprevir and a lesser impact on exposure to ritonavir. Therefore, co-administration of danoprevir/ritonavir with potent OATP inhibitors should be undertaken with appropriate precautions.

Everson GT, Cooper C, Hézode C, et al. High SVR rates with 12 to 24 weeks of ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology. 2012;56(4 Suppl):552A.

Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol. 2011;55(5):972–9.PubMedCrossRef

Reddy MB, Chen Y, Haznedar JO, et al. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug–drug interaction study. Clin Pharmacokinet. 2012;51(7):457–65.PubMedCrossRef

Goelzer P, Morcos PN, Tran J, et al. Coadministration of ritonavir with the HCV protease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo. Hepatology. 2012;56(4 Suppl):580A.

Eley T, Han Y-H, Huang S-P, et al. In vivo and in vitro assessment of asunaprevir as an inhibitor and substrate of OATP transporters in healthy volunteers. Rev Antivir Ther Infect Dis. 2012;6:7.

Park S, Ward W, Beaudet B, et al. In vitro assessment of potential drug–drug interactions between telaprevir and cyclophilin inhibitors in the treatment of chronic hepatitis C. Hepatology. 2011;54(Suppl S1):540A.

Reddy MB, Morcos PN, Le Pogam S, et al. Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother. 2012;56(6):3144–56.PubMedCrossRef

Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008;52(12):4432–41.PubMedCrossRef

Portmann R, Meille C, Poirier A. Danoprevir: in vitro studies on hepatic active uptake in human hepatocytes. Nutley: Hoffmann-La Roche Inc; 2012 (data on file).

10.

Wen B, Huang J. In vivo metabolism of danoprevir. Nutley: Hoffmann-La Roche Inc; 2012 (data on file).

11.

Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.PubMedCrossRef

12.

Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45–78.PubMedCrossRef

13.

Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–80.PubMed

14.

Treiber A, Schneiter R, Häusler S, et al. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400–7.PubMedCrossRef

15.

Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167–77.PubMedCrossRef

16.

Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002;40(10):439–50.PubMed

17.

Binet I, Wallnöfer A, Weber C, et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000;57:224–31.PubMedCrossRef

18.

Neoral^® (cyclosporine capsules, USP). US prescribing information. New Jersey: Novartis Pharmaceuticals Corporation; 2012.

19.

Morcos PN, Moreira S, Navarro M, et al. Ritonavir-boosted danoprevir (DNVr) may be co-administered without regard to meals or in combination with ranitidine or omeprazole: results of a healthy volunteer pharmacokinetic study. Rev Antiviral Ther Infect Dis. 2012;6:7.

20.

Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705.PubMedCrossRef

21.

Ding R, Tayrouz Y, Reidel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76(1):73–84.PubMedCrossRef

22.

Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323–38.PubMedCrossRef

23.

Keogh J, Kunta J. Development, validation and utility of an in vitro technique for assessment of potential clinical drug–drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006;27(5):543–54.PubMedCrossRef

24.

Reddy MB, Connor A, Brennan BJ, et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos. 2011;32(5):261–75.PubMedCrossRef

25.

Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1(4):382–6.PubMedCrossRef

26.

Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62(3):311–21.PubMedCrossRef

27.

Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25(4):2732–4.PubMed

28.

Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57:1147–52.PubMedCrossRef

29.

Morcos PN, Chang L, Zhang Y, et al. Danoprevir (DNV) does not change effects of ritonavir (RTV) on the PK of CYP3A substrate midazolam (MDZ) and CYP2C9 substrate warfarin (WAR). Rev Antiviral Ther Infect Dis. 2011;6:4.

30.

Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58(1):15–9.PubMedCrossRef

31.

Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275–91.PubMedCrossRef

32.

Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant. 2004;10(7):939–44.CrossRef

33.

Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between amprenavir/ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc. 2006;38(4):1138–40.PubMedCrossRef

Title: Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin
Authors: Barbara J. Brennan
Sebastian A. Moreira
Peter N. Morcos
Mercidita T. Navarro
Jiney Asthappan
Petra Goelzer
Paul Weigl
Patrick F. Smith
Publication date: 01-09-2013
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 9/2013
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-013-0077-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

Abstract

Background

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

Clinical Pharmacology of Axitinib

Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients

A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole

Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects

Ginkgo biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients

Pharmacokinetic–Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients